191 related articles for article (PubMed ID: 38311733)
21. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
Li C; Wang Q; Luo Y; Xiang J
Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
23. Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer.
Yu J; Liu TT; Liang LL; Liu J; Cai HQ; Zeng J; Wang TT; Li J; Xiu L; Li N; Wu LY
Cancer Cell Int; 2021 Jul; 21(1):353. PubMed ID: 34229669
[TBL] [Abstract][Full Text] [Related]
24. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR-374a-5p in ovarian cancer.
Hao T; Huang S; Han F
Cell Biochem Funct; 2020 Dec; 38(8):1089-1099. PubMed ID: 32638404
[TBL] [Abstract][Full Text] [Related]
25. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract][Full Text] [Related]
26. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
27. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer.
Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X
Oncotarget; 2015 Sep; 6(28):25381-9. PubMed ID: 26299803
[TBL] [Abstract][Full Text] [Related]
28. Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
Miao F; Zhang X; Cao Y; Wang Y; Zhang X
BMC Cancer; 2017 Dec; 17(1):838. PubMed ID: 29228922
[TBL] [Abstract][Full Text] [Related]
29. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Weng H; Feng X; Lan Y; Zheng Z
J Ovarian Res; 2021 Jun; 14(1):82. PubMed ID: 34162426
[TBL] [Abstract][Full Text] [Related]
30. Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer.
Zhang J; Zhang J; Wang F; Xu X; Li X; Guan W; Men T; Xu G
J Cell Physiol; 2021 Oct; 236(10):6907-6919. PubMed ID: 33655494
[TBL] [Abstract][Full Text] [Related]
31. TRIM37 promotes the aggressiveness of ovarian cancer cells and increases c-Myc expression by binding to HUWE1.
Li D; Zhang Z
Arch Biochem Biophys; 2022 Oct; 728():109372. PubMed ID: 35921902
[TBL] [Abstract][Full Text] [Related]
32. MiR-198 inhibits proliferation, invasion and migration of ovarian cancer cells by regulating the PI3K/Akt signaling pathway.
Xiao H; Zheng Y; Chen J; Shen H
Acta Biochim Pol; 2021 Jun; 68(4):673-677. PubMed ID: 34181826
[TBL] [Abstract][Full Text] [Related]
33. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-induced ANGPTL4 sustains tumour growth and anoikis resistance through different mechanisms in scirrhous gastric cancer cell lines.
Baba K; Kitajima Y; Miyake S; Nakamura J; Wakiyama K; Sato H; Okuyama K; Kitagawa H; Tanaka T; Hiraki M; Yanagihara K; Noshiro H
Sci Rep; 2017 Sep; 7(1):11127. PubMed ID: 28894280
[TBL] [Abstract][Full Text] [Related]
35. miR-29c-3p regulates proliferation and migration in ovarian cancer by targeting KIF4A.
Feng S; Luo S; Ji C; Shi J
World J Surg Oncol; 2020 Dec; 18(1):315. PubMed ID: 33261630
[TBL] [Abstract][Full Text] [Related]
36. A transcription factor that promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of ovarian cancer cells and its possible mechanisms.
Qi Y; Mo K; Zhang T
Biomed Eng Online; 2021 Aug; 20(1):83. PubMed ID: 34399777
[TBL] [Abstract][Full Text] [Related]
37. Role of the KRT7 Biomarker in Immune Infiltration and Paclitaxel Resistance in Ovarian.
Wang S; Li H; Li M; Liu X; Yu S; Huang H; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):132-140. PubMed ID: 37023314
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
39. Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer.
Wei C; Liu X; Wang Q; Li Q; Xie M
Int J Endocrinol; 2021; 2021():4156187. PubMed ID: 34950205
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of NCAPG in ovarian cancer is associated with ovarian cancer proliferation and apoptosis via p38 MAPK signaling pathway.
Yu H; Zou D; Ni N; Zhang S; Zhang Q; Yang L
J Ovarian Res; 2022 Aug; 15(1):98. PubMed ID: 35986371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
